FDA
-
-
-
-
-
-
-
Spruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS Symposium
-
-
-
-
-
-
-
Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)
-
-
-
-
-
-
-
Spruce Biosciences, Inc. (SPRB) PT Raised to $160 at Leerink Partners
-
-
-
-
-
-
-
Spruce Biosciences Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)
-
-
-
-
-
-
-
Spruce Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates
-
-
-
-
-
-
-
Spruce Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Recent Corporate Updates
-
-
-
323,754 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

